Clinical Trial

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

A new therapy claims to reverse cellular aging to cure disease, but its patient-funded trial model sparks a debate on equity and medical ethics.

Weight Watchers now offers the new Wegovy pill, a needle-free option, betting its future on combining powerful GLP-1 drugs with its classic support.

Tango Therapeutics adds seasoned CFO Sung Lee to its board, a strategic move to guide its lead cancer drug, vopimetostat, through late-stage trials.

Known for hair styling, Wavytalk is launching a clinically-tested LED mask. Can this at-home device truly rival professional skincare treatments?

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

INOVIO's promising non-surgical treatment for a rare disease faces FDA scrutiny, casting doubt on its fast-track approval and impacting patient hopes.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Early data shows QurAlis' QRL-101 successfully engaged its intended target in ALS patients, a key step for a novel drug aimed at quelling neuronal storm.

Adlai Nortye licenses its promising pan-RAS cancer inhibitor to ASK Pharm for Greater China in a deal valued at up to $230 million.

A new oral drug, cadisegliatin, enters a major clinical trial in the UAE, aiming to help Type 2 diabetes patients struggling with insulin therapy.

With trial data showing an average 23% body weight loss, Novo Nordisk's new combination drug CagriSema could usher in a powerful new era for medicine.

A new FDA approval for an EGFR-mutated lung cancer therapy cuts treatment from hours to minutes, offering new hope and convenience for thousands of patients.

With FDA & EMA alignment, atebimetinib heads to a Phase 3 trial, offering new hope against deadly pancreatic cancer based on promising early survival data.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.